Shopping Cart
- Remove All
- Your shopping cart is currently empty
TM5441 is an orally bioavailable fibrinogen activator inhibitor-1 inhibitor that inhibits several cancer cell lines with IC50 values ranging from 13.9 to 51.1 μM.It induces intrinsic cell death in several human cancer cells and attenuates Nω-nitro-1-arginine methyl ester-induced cardiac hypertension and vascular senescence.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $34 | In Stock | |
2 mg | $48 | In Stock | |
5 mg | $79 | In Stock | |
10 mg | $122 | In Stock | |
25 mg | $263 | In Stock | |
50 mg | $493 | In Stock | |
100 mg | $701 | In Stock | |
500 mg | $1,460 | In Stock |
Description | TM5441 is an orally bioavailable fibrinogen activator inhibitor-1 inhibitor that inhibits several cancer cell lines with IC50 values ranging from 13.9 to 51.1 μM.It induces intrinsic cell death in several human cancer cells and attenuates Nω-nitro-1-arginine methyl ester-induced cardiac hypertension and vascular senescence. |
Targets&IC50 | Tumor cell lines:9.7~60.3 μM |
In vitro | METHODS: TM5441 (1-100μM) was used to further study the survival of HT1080, HCT116, Daoy, MDA-MB-231 and Jurkat. RESULTS Cell viability treated with TM5441 significantly decreased in a dose-dependent manner by 50%, ranging between 13.9 and 51.1μM.[2] METHODS: Cultures of human endothelial cells EA.hy926 were pretreated with TM5441 (10 μM) for 24 h and then treated with doxorubicin (Dox) in triplicate for 4 days. Total protein and RNA were collected from three independently treated wells and combined to explore the protective effect of TM5441 on Dox-induced cellular senescence. RESULTS TM5441 treatment inhibited Dox-induced expression levels of p53, PAI-1, p16, p21 and IGFBP3 in human endothelial cells. [3] |
In vivo | METHODS: High-fat diet (HFD)-fed C57BL/6J mice were treated with 20 mg/kg of TM5441 daily to study the effect of TM5441, an oral PAI-1 inhibitor that lacks bleeding risk, on HFD-induced NAFLD. RESULTS Early and delayed treatment with TM5441 reduced hepatic steatosis, and both strategies abolished hepatic insulin resistance and mitochondrial dysfunction, manifested by enhanced p-Akt and p-GSK3β, reduced p-JNK signaling, and p-AMPK and PGC-1α activation. [1] |
Kinase Assay | TM5441 is dissolved with DMSO at a stock concentration of 50 mM.HT1080, HCT116, Daoy, MDA-MB-231 and Jurkat cells are treated with 0-100 μM TM5441 for 48 hours at 37°C. Cell viability is measured by MTT assay. |
Animal Research | TM5441 is prepared in 0.5% carboxymethyl cellulose.Mice: TM5275 at 50 mg/kg/day and TM5441 at 10 mg/kg/day were orally administered in control and diabetic mice for 16 weeks. Mice were monitored at least once a day. At the end, blood is collected for measurement of plasma glucose and creatinine, urine for protein measurement, and kidneys for immunohistochemical analysis. |
Molecular Weight | 428.82 |
Formula | C21H17ClN2O6 |
Cas No. | 1190221-43-2 |
Smiles | OC(=O)c1cc(Cl)ccc1NC(=O)COCC(=O)Nc1cccc(c1)-c1ccoc1 |
Relative Density. | 1.451 g/cm3 (Predicted) |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO: < 1 mg/mL (insoluble) |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.